electroCore, Inc. - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of electroCore, Inc. Company

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Company’s product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Company’s TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.

electroCore, Inc. Info



Ticker SymbolECOR

Company nameelectroCore, Inc.

IPO dateJun 22, 2018

CEOMr. Daniel S. Goldberger

Number of employees73

Security typeOrdinary Share

Fiscal year-endJun 22

Address200 Forge Way

CityROCKAWAY

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code07866

Phone19732900097

Websitehttps://www.electrocore.com/

Ticker SymbolECOR

IPO dateJun 22, 2018

CEOMr. Daniel S. Goldberger

Company Executives of electroCore, Inc.



Name

Name/Position

Position

Shareholding

Change

Mr. Daniel S. (Dan) Goldberger

Chief Executive Officer, Director

184.90K

+0.54%

Mr. Thomas M. (Tom) Patton, J.D.

Independent Director

102.78K

+22.69%

Mr. John P. Gandolfo

Independent Director

88.10K

+27.52%

Ms. Patricia Wilber

Independent Director

72.33K

+35.66%

Ms. Elena Bonfiglioli

Director

30.55K

--

Dr. Thomas J. Errico, M.D.

Independent Chairman of the Board

--

Mr. Joshua S. Lev

Chief Financial Officer

--

Ms. Julie A. Goldstein

Independent Director

--

Mr. James C. Theofilos

Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Daniel S. (Dan) Goldberger

Chief Executive Officer, Director

184.90K

+0.54%

Mr. Thomas M. (Tom) Patton, J.D.

Independent Director

102.78K

+22.69%

Mr. John P. Gandolfo

Independent Director

88.10K

+27.52%

Ms. Patricia Wilber

Independent Director

72.33K

+35.66%

Ms. Elena Bonfiglioli

Director

30.55K

--

Dr. Thomas J. Errico, M.D.

Independent Chairman of the Board

--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Rx gammaCore - Department of Veteran Affairs and Department of Defense

5.18M

70.25%

Truvaga

994.00K

13.47%

Outside the United States

465.00K

6.30%

Rx gammaCore - U.S. Commercial

394.00K

5.34%

TAC-STIM

181.00K

2.45%

Other

162.00K

2.19%

By RegionUSD

Name

Revenue

Proportion

United States

6.89M

93.42%

United Kingdom

433.00K

5.87%

Other

36.00K

0.49%

Japan

17.00K

0.23%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Rx gammaCore - Department of Veteran Affairs and Department of Defense

5.18M

70.25%

Truvaga

994.00K

13.47%

Outside the United States

465.00K

6.30%

Rx gammaCore - U.S. Commercial

394.00K

5.34%

TAC-STIM

181.00K

2.45%

Other

162.00K

2.19%

Shareholding Stats

Updated: Sun, Sep 14

Shareholders

Shareholder Types

Shareholders

Proportion

Zhang (Tianyi)

9.19%

Theofilos (Charles Steve)

5.56%

Hilve Holdings Ltd

5.40%

Errico (Thomas J.)

3.83%

AWM Investment Company, Inc.

3.38%

Other

72.64%

Shareholders

Proportion

Zhang (Tianyi)

9.19%

Theofilos (Charles Steve)

5.56%

Hilve Holdings Ltd

5.40%

Errico (Thomas J.)

3.83%

AWM Investment Company, Inc.

3.38%

Other

72.64%

Shareholder Types

Shareholders

Proportion

Individual Investor

26.98%

Corporation

8.76%

Investment Advisor

7.19%

Investment Advisor/Hedge Fund

4.70%

Hedge Fund

2.52%

Research Firm

0.24%

Pension Fund

0.03%

Other

49.58%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

70

1.17M

14.68%

-263.78K

2025Q2

83

3.54M

47.26%

+919.62K

2025Q1

79

2.97M

41.24%

+583.46K

2024Q4

81

2.54M

38.89%

+127.67K

2024Q3

72

2.68M

41.45%

+353.98K

2024Q2

75

2.58M

42.20%

+349.71K

2024Q1

80

2.10M

35.02%

-224.03K

2023Q4

78

2.23M

37.11%

+633.96K

2023Q3

84

2.11M

37.42%

+276.86K

2023Q2

89

1.49M

31.36%

-816.60K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Zhang (Tianyi)

734.64K

9.25%

+734.64K

--

May 15, 2025

Theofilos (Charles Steve)

444.53K

5.6%

--

Jul 04, 2025

Hilve Holdings Ltd

432.00K

5.44%

+432.00K

--

Aug 15, 2025

Errico (Thomas J.)

306.38K

3.86%

+26.61K

+9.51%

Sep 02, 2025

AWM Investment Company, Inc.

269.93K

3.4%

-48.18K

-15.15%

Jun 30, 2025

The Vanguard Group, Inc.

232.33K

2.92%

--

Jun 30, 2025

Goldberger (Daniel S)

184.90K

2.33%

+1.00K

+0.54%

Aug 11, 2025

Renaissance Technologies LLC

180.69K

2.27%

+2.26K

+1.27%

Jun 30, 2025

Happy Holstein Management, LLC

153.17K

1.93%

--

Jul 04, 2025

MAZ Partners, L.P.

115.52K

1.45%

-156.44K

-57.52%

May 13, 2025

Related ETFs



Updated: Sun, Nov 2

Name

Proportion

iShares Micro-Cap ETF

0.01%

iShares Micro-Cap ETF

Proportion0.01%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Feb 14, 2023

Merger

15→1

Feb 14, 2023

Merger

15→1

Feb 14, 2023

Merger

15→1

Feb 14, 2023

Merger

15→1

Date

Type

Ratio

Feb 14, 2023

Merger

15→1

Feb 14, 2023

Merger

15→1

Feb 14, 2023

Merger

15→1

Feb 14, 2023

Merger

15→1